Overall reduction of splenomegaly by > 50% occurred in 79% of MF patients on combination ruxolitinib plus azacitidine.
Lenalidomide can restore epoetin alfa sensitivity in lower-risk MDS patients refractory or unresponsive to erythropoiesis stimulating agents.
ORR 60% among patients with lower-risk MDS treated with low-dose azacitidine or decitabine.
Daily oral enasidenib monotherapy shows activity in a small cohort of patients with predominately high-risk mIDH2 MDS, including some who failed prior HMA treatment.
Preliminary phase II data suggest promising activity of single-agent ipilimumab and nivolumab plus azacitidine in a molecularly high-risk population of MDS patients.
Results from the phase III trial showed fewer treatment-related AEs, dose reductions, and secondary malignancies in patients receiving ropeginterferon α-2b compared with those receiving hydroxyurea.
Sotatercept well tolerated with response observed in 36% of evaluable patients.
Results from interim analysis of phase III trial found no difference in CR at 12 months between therapies, and grade ≥ 3 AEs occurred more frequently in patients receiving pegIFN α-2a.
In this Expert Analysis, Jamile Shammo, MD, FASCP, FACP, and Rami S. Komrokji, MD, discuss the clinical applicability of new, key findings in myelodysplastic syndromes and myeloproliferative neoplasms presented at Hematology 2016.
In this downloadable slideset, Rami S. Komrokji, MD, and Jamile Shammo, MD, FASCP, FACP, highlight the key data presented at the 2016 Hematology annual meeting.